Skip to search formSkip to main contentSkip to account menu

2-hydroxydesipramine

Known as: 2-OH-DMI, 2-hydroxy-desipramine, 2-hydroxydesmethylimipramine 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1997
Highly Cited
1997
Cytochrome P450 (CYP) involved in the two major pathways of imipramine (IMI) was reappraised using human liver microsomes… 
1993
1993
OBJECTIVE To assess the developmental effects of desipramine (DMI) treatment on the electrocardiogram (ECG), we investigated… 
Highly Cited
1988
Highly Cited
1988
Urinary excretion of desipramine (DMI) and 2‐hydroxydesipramine (2‐OH‐DMI) after single oral doses of 25 mg DMI was investigated… 
1988
1988
We describe the relationship of 2‐hydroxydesipramine (OH‐DMI) plasma levels and response in a prospective DMI study in which… 
Highly Cited
1987
Highly Cited
1987
The 2‐hydroxylation of desmethylimipramine (DMI) was studied in 14 healthy subjects previously phenotyped with respect to… 
Highly Cited
1984
Highly Cited
1984
The 2‐hydroxylation of desmethylimipramine (DMI) and the 4‐hydroxylation of debrisoquine (D) were studied in healthy subjects and… 
1984
1984
Plasma levels of desipramine (DMI) and the unconjugated form of its principal metabolite 2‐hydroxydesipramine (OH‐D) were… 
1971
1971
1. Imipramine and its oxidized metabolites 2-hydroxyimipramine, desmethylimipramine (DMI), 2-hydroxydesmethylimipramine (2-OH-DMI…